Assessment of Elevated Serum Tumor Markers Carcinoembryonic Antigen (CEA) and Cancer Antigen 15-3 (CA15-3) among Patients with Different Subtypes of Metastatic Breast Cancer
Background: Cancer antigen 15-3 and carcinoembryonic antigen are used in clinical and laboratory diagnosis of metastatic breast cancer. Previous studies have noted conflicting results about the association between carcinoembryonic antigen and cancer antigen 15-3 in metastatic breast cancer. The p...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Shiraz University of Medical Sciences
2019-01-01
|
Series: | Middle East Journal of Cancer |
Subjects: | |
Online Access: | http://mejc.sums.ac.ir/index.php/mejc/article/view/800 |
Summary: | Background: Cancer antigen 15-3 and carcinoembryonic antigen are used in clinical and
laboratory diagnosis of metastatic breast cancer. Previous studies have noted conflicting results
about the association between carcinoembryonic antigen and cancer antigen 15-3 in metastatic
breast cancer. The present study examined serum tumor marker levels of carcinoembryonic antigen
and cancer antigen 15-3 among patients with different subtypes of metastatic breast cancer.
Methods: In this cross-sectional study, we assessed metastatic breast cancer patients
diagnosed between 2005 and 2012 who referred to academic Hospitals affiliated with Mashhad
University of Medical Sciences. The patients were selected by systematic randomization
sampling. Demographic, clinical, pathological, and therapeutic data were collected from
patients’ hospital records. Statistical analyses were performed by Statistical Package for the Social
Sciences version 16.0 software.
Results: A total of 298 eligible patients enrolled in the study. Patients’ median age was
48.39±12.57 years. Elevated serum levels of carcinoembryonic antigen were identified in
65.17% of patients and cancer antigen 15-3 in 57.29% of patients. Based on molecular subtype
categorization, 109 (39.5%) patients were human epidermal growth factor receptor 2 negative
and 105 (38.0%) patients were in the luminal group. There was no significant correlation between
serum carcinoembryonic antigen and cancer antigen 15-3 with subtypes of the tumor. The most
common sites for metastasis were bones and liver, respectively. However, there was no
significant correlation between serum carcinoembryonic antigen and cancer antigen 15-3 with
the site of metastasis. There was a significant association between serum carcinoembryonic antigen
level and stages IIA and IV.
Conclusion: One of the most significant findings of the current study was the increased serum
carcinoembryonic antigen and cancer antigen 15-3 levels in most metastatic breast cancer
participants. We postulate that regular measurement of serum cancer antigen 15-3 and carcinoembryonic
antigen could be useful for earlier detection and prediction of outcomes. |
---|---|
ISSN: | 2008-6709 2008-6687 |